tHEORetically Speaking

HealthEconomics.com
  • 0,0 (0)
  • БИОНАУКИ
  • ДВАЖДЫ В НЕДЕЛЮ

Insights, observations, and executive interviews that discuss data and evidence to guide value-based decisions in health care. For more, visit our blog: https://healtheconomics.com/theoretically-speaking/

  1. Integrated Evidence Delivery: Why HEOR belongs at the heart of the Modern CRO

    -2 ДН.

    Integrated Evidence Delivery: Why HEOR belongs at the heart of the Modern CRO

    In this episode, we explore why the traditional 'clinical-first, value-later' model is becoming a strategic liability and why integrating HEOR into CRO operations is the new industry standard. Join us as Aaron Berger and Dr. Mir Sohail Fazeli break down how to eliminate vendor silos to build a seamless, lifecycle-wide evidence narrative that ensures regulatory success. To learn more about this, check out the deep-dive blog here: https://healtheconomics.com/integrated-evidence-delivery-the-strategic-role-of-heor-in-modern-cros

    32 мин.
  2. Weekly News Roundup — RSV Breakthrough Data, Psychedelic Approvals on the Horizon, and Major FDA Policy Shifts

    -5 ДН. · БОНУСНЫЙ КОНТЕНТ

    Weekly News Roundup — RSV Breakthrough Data, Psychedelic Approvals on the Horizon, and Major FDA Policy Shifts

    This week’s tHEORetically Speaking News Roundup covers new real-world data showing Sanofi’s Beyfortus delivering multi-season protection against RSV hospitalizations, Compass Pathways’ positive Phase 3 results for its psilocybin therapy in treatment-resistant depression, and the FDA’s move toward a single-trial approval standard. We also explore stabilizing telehealth utilization trends and new FDA scrutiny of SSRI and RSV antibody safety.  Tune in for this concise recap of these pivotal industry updates!

    5 мин.
  3. Weekly News Roundup — AI Drug Discovery Deals, mRNA Regulatory Setbacks, and Global Investment Shifts

    13 ФЕВР. · БОНУСНЫЙ КОНТЕНТ

    Weekly News Roundup — AI Drug Discovery Deals, mRNA Regulatory Setbacks, and Global Investment Shifts

    This week’s tHEORetically Speaking News Roundup covers Takeda’s $1.7B AI-powered drug discovery partnership with Iambic, Moderna’s FDA setback for its mRNA flu vaccine, and AstraZeneca’s decision to keep UK investments on hold despite new pricing reforms. We also explore the launch of a European Life Sciences Coalition aimed at strengthening biotech funding and competitiveness across the EU. Tune in for this concise recap of these pivotal industry updates!  Register for World EPA Congress 2026 here: https://www.terrapinn.com/EPA/2026/HealthEconomics

    4 мин.
  4. Weekly News Roundup — Regulatory RWE Battles, Capital Market Moves, and Cash-Pay Drug Pricing Disruption

    6 ФЕВР. · БОНУСНЫЙ КОНТЕНТ

    Weekly News Roundup — Regulatory RWE Battles, Capital Market Moves, and Cash-Pay Drug Pricing Disruption

    This week's tHEORetically Speaking News Roundup covers Humana’s rollout of a Google Cloud–powered AI tool to streamline 80 million annual member calls, Amgen’s pushback against the FDA to keep Tavneos on the market using real-world evidence, and AstraZeneca’s NYSE debut to fuel its global growth strategy. We also explore the new TrumpRx portal aimed at expanding discounted cash-pay prescriptions.  Tune in for this concise recap of these pivotal industry updates!  Register for World EPA Congress 2026 here: https://www.terrapinn.com/EPA/2026/HealthEconomics

    5 мин.
  5. INsights & OUTcomes with Taylor Hirschberg

    2 ФЕВР.

    INsights & OUTcomes with Taylor Hirschberg

    This episode features Taylor Hirschberg, an award winning writer, activist, and academic. He is the CEO of Metli Consulting, an inclusive consultancy firm focused on helping to prepare for launch and providing a faster, more flexible approach to market access. Learn more about Metli Consulting: https://www.metliconsulting.com/ “Science without story fails to reach policymakers. Policy without equity fails communities. Story without evidence fails everyone. Metli is a life sciences and public health consulting firm founded at the intersection of science, policy, communications, and human impact.”

    28 мин.
  6. Weekly News Roundup — Rare Disease Funding Risks, Medicare Advantage Reform, and Global Trade Shifts

    30 ЯНВ. · БОНУСНЫЙ КОНТЕНТ

    Weekly News Roundup — Rare Disease Funding Risks, Medicare Advantage Reform, and Global Trade Shifts

    This week’s tHEORetically Speaking News Roundup covers the looming funding crisis for rare disease biotechs as FDA priority review vouchers expire, CMS’s proposed crackdown on Medicare Advantage upcoding, and Cellares’ $257 million raise to scale automated cell therapy manufacturing. We also explore Sanofi’s defense of vaccines amid shifting U.S. policy and a landmark EU–India free trade agreement set to reshape global pharma access.  Tune in for a concise recap of these pivotal industry updates!

    5 мин.
  7. Weekly News Roundup — Oral GLP-1 Momentum, Trade Tensions, EU Drug Security, and AI Risk Warnings

    23 ЯНВ. · БОНУСНЫЙ КОНТЕНТ

    Weekly News Roundup — Oral GLP-1 Momentum, Trade Tensions, EU Drug Security, and AI Risk Warnings

    This week’s tHEORetically Speaking News Roundup covers Novo Nordisk’s early momentum with oral Wegovy amid intensifying GLP-1 competition, rising geopolitical trade tensions threatening pharma market access, and Europe’s push to secure medicine supply chains through the Critical Medicines Act. We also examine new warnings on the misuse of medical AI heading into 2026.  Tune in for this concise recap of the week’s most impactful HEOR, RWE, and market access developments.

    3 мин.
  8. Weekly News Roundup — Neurodegeneration Deals, Generative AI, and Drug Pricing Politics

    16 ЯНВ. · БОНУСНЫЙ КОНТЕНТ

    Weekly News Roundup — Neurodegeneration Deals, Generative AI, and Drug Pricing Politics

    This week’s tHEORetically Speaking News Roundup covers Novartis’ $1.5B Alzheimer’s licensing deal, the FDA’s push to accelerate drug development through Bayesian trial methods, and Bayer’s move to scale generative AI in antibody discovery. We also break down Oxford Biomedica’s takeover talks and a newly unveiled US healthcare cost plan. Tune in for a concise recap of these pivotal industry updates!

    4 мин.
См. все (77)

Об этом подкасте

Insights, observations, and executive interviews that discuss data and evidence to guide value-based decisions in health care. For more, visit our blog: https://healtheconomics.com/theoretically-speaking/

Информация

  • Автор
    HealthEconomics.com
  • Годы выхода
    2025 - 2026
  • Выпуски
    77
  • Ограничения
    С ненормативной лексикой
  • Авторские права
    © 2026 tHEORetically Speaking
  • Сайт подкаста
    tHEORetically Speaking